Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas.

Papachristodoulou A, Silginer M, Weller M, Schneider H, Hasenbach K, Janicot M, Roth P.

Clin Cancer Res. 2019 Dec 1;25(23):7189-7201. doi: 10.1158/1078-0432.CCR-17-3024. Epub 2019 Sep 17.

PMID:
31530630
2.

Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.

Le Rhun E, von Achenbach C, Lohmann B, Silginer M, Schneider H, Meetze K, Szabo E, Weller M.

Int J Cancer. 2019 Jul 1;145(1):242-253. doi: 10.1002/ijc.32069. Epub 2019 Jan 12.

PMID:
30549269
3.

Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes.

Papachristodoulou A, Signorell RD, Werner B, Brambilla D, Luciani P, Cavusoglu M, Grandjean J, Silginer M, Rudin M, Martin E, Weller M, Roth P, Leroux JC.

J Control Release. 2019 Feb 10;295:130-139. doi: 10.1016/j.jconrel.2018.12.009. Epub 2018 Dec 8.

PMID:
30537486
4.

The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.

Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SS, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, Weller M, Eisele G.

Acta Neuropathol. 2018 Jun;135(6):923-938. doi: 10.1007/s00401-018-1836-9. Epub 2018 Mar 20.

PMID:
29557506
5.

Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma.

Happold C, Stojcheva N, Silginer M, Weiss T, Roth P, Reifenberger G, Weller M.

J Neurochem. 2018 Mar;144(6):780-790. doi: 10.1111/jnc.14326.

6.

NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.

Weiss T, Schneider H, Silginer M, Steinle A, Pruschy M, Polić B, Weller M, Roth P.

Clin Cancer Res. 2018 Feb 15;24(4):882-895. doi: 10.1158/1078-0432.CCR-17-1766. Epub 2017 Nov 21.

7.

Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma.

Silginer M, Nagy S, Happold C, Schneider H, Weller M, Roth P.

Neuro Oncol. 2017 Oct 1;19(10):1338-1349. doi: 10.1093/neuonc/nox051.

8.

Biological activity of tumor-treating fields in preclinical glioma models.

Silginer M, Weller M, Stupp R, Roth P.

Cell Death Dis. 2017 Apr 20;8(4):e2753. doi: 10.1038/cddis.2017.171.

9.

Control of glioma cell migration and invasiveness by GDF-15.

Codó P, Weller M, Kaulich K, Schraivogel D, Silginer M, Reifenberger G, Meister G, Roth P.

Oncotarget. 2016 Feb 16;7(7):7732-46. doi: 10.18632/oncotarget.6816.

10.

The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway.

Silginer M, Burghardt I, Gramatzki D, Bunse L, Leske H, Rushing EJ, Hao N, Platten M, Weller M, Roth P.

Oncogene. 2016 Jun 23;35(25):3260-71. doi: 10.1038/onc.2015.387. Epub 2015 Oct 26.

PMID:
26500056
11.

Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.

Happold C, Roth P, Silginer M, Florea AM, Lamszus K, Frei K, Deenen R, Reifenberger G, Weller M.

Mol Cancer Ther. 2014 Apr;13(4):948-61. doi: 10.1158/1535-7163.MCT-13-0772. Epub 2014 Feb 13.

12.

Integrin inhibition promotes atypical anoikis in glioma cells.

Silginer M, Weller M, Ziegler U, Roth P.

Cell Death Dis. 2014 Jan 23;5:e1012. doi: 10.1038/cddis.2013.543.

13.

Integrin control of the transforming growth factor-β pathway in glioblastoma.

Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M.

Brain. 2013 Feb;136(Pt 2):564-76. doi: 10.1093/brain/aws351. Epub 2013 Jan 31.

14.

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.

Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M.

J Neurochem. 2012 Jul;122(2):444-55. doi: 10.1111/j.1471-4159.2012.07781.x. Epub 2012 May 28.

Supplemental Content

Loading ...
Support Center